But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
ApexOnco Front Page
Recent articles
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
The Titan CD8-guiding technology seems to have spawned a new variant.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A single-arm trial was enough for J&J’s Inlexzo nod.
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
ESMO and the Triple Meeting approach.
